eNews
Home page > Comments


Comments

Biogen, Elan seek okay for first-line Tysabri use in MS

17.01.2013. | LONDON (Reuters) - Biogen Idec and Elan have filed for approval to sell their drug Tysabri as a first-line treatment for multiple sclerosis, a move that could boost sales of the drug....


Оставите Ваш коментр
*Име:

Е-пошта:


*Ваш коментар:
:) :D ;) B-) :P :-o :( x-(

*Сигурносни број: